NEW YORK, Oct. 27, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. (“Shattuck” or “the Company”) (NASDAQ: STTK). Investors who purchased Shattuck securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/STTK.
Investigation Details
On October 1, 2024, Shattuck issued a press release announcing the discontinuation of its lead experimental therapy SL-172154 following disappointing early-stage data. Specifically, Shattuck’s decision came after an interim Phase 1 readout indicated that SL-172154, compared to azacitidine monotherapy, failed to improve median overall survival in certain patients with myeloid leukemia and myelodysplastic syndromes in combination with azacitidine. On this news, Shattuck’s stock price fell $1.57 per share, or 44.99%, to close at $1.92 per share on October 1, 2024.
What's Next?
If you are aware of any facts relating to this investigation or purchased Shattuck securities, you can assist this investigation by visiting the firm’s site: bgandg.com/STTK. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com